Navigation Links
Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients
Date:6/8/2009

Pre-heparinization Limits Clot Retention and Decreases Residual Clot Volume

SAN FRANCISCO, June 8 /PRNewswire/ -- MAQUET Cardiovascular LLC announced today that data presented at the annual meeting of the International Society for Minimally Invasive Cardiothoracic Surgery show that administration of a heparin bolus with doses as low as 2500U prior to endoscopic vein harvest (EVH) was associated with improved acute saphenous vein (SV) graft patency in patients undergoing off-pump coronary artery bypass (OPCAB). Pre-heparinization was also linked to a significant reduction in the incidence and volume of residual clot strands within the vein.

In EVH, a small incision is made in the leg, through which an endoscope is passed and the vein harvested for coronary artery bypass graft (CABG) procedures. This method reduces patient discomfort and scarring.

EVH also significantly reduces wound complications and hastens recovery time compared to traditional techniques that involve a long incision to expose the entire length of the vein.

"In our experience, the impact of pre-heparinization on surgical bleeding is minimal, making it a promising strategy that may improve patient outcomes with minimally invasive vein harvesting," said lead investigator Robert Poston, M.D., Chief, Division of Cardiac Surgery, Boston University.

The prospective study examined acute patency rates in 460 patients that underwent OPCAB using veins acquired through EVH, comparing patients receiving no heparin prior to harvest (n=306) to those who received one of three doses of heparin prior to the procedure (n=181). A subset of the most recent 110 patients underwent catheter-based infrared imaging (OCT) of the full tract of harvested SV in order to measure residual clot within the vein. Overall, vein graft patency was 98.9 percent in patients treated with heparin compared to 95.2 percent in the controls (p<0.05). In the subset of the most recent patients, 42 percent of patients receiving pre-heparinization showed residual clot in the harvested vein compared with 85 percent of patients that didn't receive heparin (p<0.05). Clot volume and the percentage of the vein containing clot were also significantly reduced with the use of heparin prior to EVH.

"These data are evidence that with pre-heparinization, EVH can be performed with excellent patency results in patients who require coronary artery bypass grafting, reinforcing the efficacy of this procedure," said Dr. Poston.

"We are encouraged by the results of this study and see it as a true advance in patient care," said Pat Walsh, Chief Operating Officer of the Cardiac Surgery division of MAQUET. "As a leader in EVH, MAQUET is committed to helping physicians continue to optimize EVH conduit quality and patient outcomes."

About MAQUET Cardiovascular

MAQUET Cardiovascular LLC is a division of MAQUET Medical Systems, part of the publicly listed Swedish group of companies GETINGE AB. MAQUET Cardiovascular was recently formed by combining MAQUET Cardiopulmonary with Boston Scientific's Vascular Surgery and Cardiac Surgery divisions, which includes the products and services of Guidant Cardiac Surgery and the VASOVIEW endoscopic vessel harvesting system. The creation of this new organization enables MAQUET to offer a comprehensive array of patient care solutions for less-invasive endoscopic vessel harvesting, off- and on-pump coronary artery bypass surgery and vascular grafts.

MAQUET has 170 years of healthcare experience, and is committed to becoming "The Gold Standard" for therapeutic medical equipment across the globe. As a market leader, MAQUET offers innovative medical solutions from three divisions: Surgical Workplaces, Critical Care and Cardiovascular.

http://www.maquet.com


'/>"/>
SOURCE MAQUET Cardiovascular LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Interface Biologics Anti-Thrombic Additives Show Equivalent Efficacy to Commercial Heparinized Coatings
2. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
3. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
4. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
5. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
6. Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis
7. FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
8. RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
9. ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments
10. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
11. REMOXY(R) NDA Filing Accepted by FDA and Priority Review Granted
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Arvinas LLC, a private biotechnology company creating ... today announced the presentation of new preclinical data on ... session at the American Society of Clinical Oncology 2017 ... FL. "The new data ... potential of PROTACs to drive durable and robust responses ...
(Date:2/17/2017)... Research and Markets has announced the addition of ... their offering. ... separate comprehensive analytics for the US, Canada , ... , Latin America , and Rest of World. ... Also, a six-year historic analysis is provided for these markets. Market data ...
(Date:2/17/2017)... 17, 2017  Featuring new and ... the  2017 HIMSS Conference & Exhibition (HIMSS17 ),  Royal ... global leader in health technology,  will ... population health management, acute healthcare informatics ... a highly secure, cloud-based ecosystem. Visitors ...
Breaking Medicine Technology:
(Date:2/17/2017)... Palos Verdes, CA (PRWEB) , ... February 17, ... ... and emotional flow is Dr. Carol Francis' goals for each and ... Retreat Conference, Dr. Carol Francis will demonstrate five different brainwave tools which help ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... at Molecular Medicine Tri-Conference February 20 – 22 in San Francisco. As part ... its anatomic and molecular pathology workflow solution, as well as its new precision ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in the greater ... LifeNet 4 Families organization. , For more than 30 years, LifeNet 4 ...
(Date:2/16/2017)... ... February 17, 2017 , ... The ... services to families and entrepreneurs in the Birmingham area, is announcing an ongoing ... needs assistance with her medically challenged son, Anius. , Anius is medically complex ...
Breaking Medicine News(10 mins):